Bionovate applies to list on NASDAQ
CHAM, Switzerland, May 03, 2021 (GLOBE NEWSWIRE) -- Bionovate Technologies Corp., traded on OTC Markets (OTCPK:BIIO), announced that it has submitted a formal application to list its common shares (“Shares”) on the NASDAQ Stock Exchange (“NASDAQ”).
Bionovate announces to reduce shares
CHAM, Switzerland, April 30, 2021 (GLOBE NEWSWIRE) -- Bionovate Technologies Corp., traded on OTC Markets (OTCPK:BIIO), announces the cancellation and return to treasury of 25,000,000 common shares of the company’s stock.
Bionovate Supports Startups in the Digital Health Markets
CHAM, Switzerland, March 04, 2021 (GLOBE NEWSWIRE) -- Bionovate Technologies Corp (OTCMKT: BIIO) (“Bionovate”), is currently in the process of compiling a shortlist for potential investments in start-ups in the digital healthcare markets, as announced.
Bionovate Announces Return of Shares to Treasury
CHAM, Switzerland, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Bionovate Technologies Corp., traded on the Nasdaq OTC (OTCPK:BIIO), announces the cancellation and return to treasury of 13,820,000 common shares of the company’s stock.
Bionovate seeks to invest in Health and Life Care Startups
CHAM, Switzerland, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Bionovate Technologies Corp., traded on the Nasdaq OTC (OTCPK:BIIO), plans to strategically invest in startups in Europe in the health and life care sector and focus its investments strategy towards on-demand healthcare services.
Bionovate realigns its strategy: from Quantify Yourself to Know Yourself
CHAM, Switzerland, Nov. 27, 2020 (GLOBE NEWSWIRE) -- The medical device company Bionovate Technologies Corp adopts a strategic reorientation under new management. Aleksandar Vucak will realign the company as CEO after taking over the majority of the shares of the company, traded on the Nasdaq OTC (OTCPK:BIIO). Bionovate Technologies Corp.
Bionovate Technologies picks up semanticom for international PR
CHAM, Switzerland and BERLIN, Oct. 17, 2020 (GLOBE NEWSWIRE) -- The Berlin public relations agency wins the business with international PR and strategic corporate communications of the medical device company Bionovate Technologies Corp. The shares of the company are traded on the Nasdaq OTC (OTCPK:BIIO).Bionovate Technologies Corp.
Where is Bionovate located?
and changed its name to Bionovate Technologies Corp. in December 2017. Bionovate Technologies Corp. was founded in 2010 and is based in Cham, Switzerland.
Where is Bionovate Technologies located?
and changed its name to Bionovate Technologies Corp. in December 2017. Bionovate Technologies Corp. was founded in 2010 and is based in Cham, Switzerland. As of September 28, 2020, Bionovate Technologies Corp. operates as a subsidiary of Human Data AG. View less.
What is equity summary score?
The Equity Summary Score is an accuracy-weighted sentiment derived from the ratings of independent research providers on Fidelity.com. It uses the past relative accuracy of the providers in determining the emphasis placed on any individual opinion. Learn More....
What is Bionovate technology?
Bionovate Technologies Corp., a medical device company, focuses on developing automated treatment for age spots. It intends to develop and provide automated computerized system that treats age spots anywhere on the body. The company targets to sell its systems to physicians and spas worldwide.
Component Grades
We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all now.
Bionovate Technologies Corp. (BIIO) Company Bio
Bionovate Technologies Corp. manufactures lighting fixtures. The Company produces and markets light-emitting diode lighting products. Bionovate Technologies serves customers in North America and China.
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Signals & Forecast
The Bio-Rad Laboratories Inc stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock.
Support, Risk & Stop-loss
On the downside, the stock finds support just below today's level from accumulated volume at $739.51 and $643.70. There is natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level.
Is Bio-Rad Laboratories Inc stock A Buy?
Bio-Rad Laboratories Inc holds several negative signals and this should be a sell candidate, but due to the general chance for a turnaround situation it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
Is biotech a volatile sector?
Biotech stocks are consistently one of the most exciting sectors with many volatile stocks. If the sector clicks with your trading style, there can be plenty of trading opportunities. But remember, as always, to do your homework.
What is an OBLN?
OBLN is a tiny firm that focuses on developing medical devices to assist in weight loss for overweight and obese people. When I say tiny, I mean it — they currently have a market cap of just over $15 million.
Where is CELG based?
CELG is based out of New Jersey and specializes in developing medicines for cancer and inflammatory disorders. It’s a big name in the sector with a current market cap north of $60 billion.
What agency does a company need to pass drug testing?
In the United States, if a company wants to develop and sell a drug to the public, they need to pass stringent testing by the government’s Food and Drug Administration Agency (FDA).
What is Axsome 05?
Axsome Therapeutics. Axsome's lead candidate drug, which it calls AXS-05, targets depression and Alzheimer’s disease-related agitation. In early 2021, the company formally filed for U.S. regulatory approval for the drug to treat depression. It’s also evaluating AXS-05 in a phase 2 study for smoking cessation.
Who makes Eylea?
Regeneron Pharmaceuticals. The biggest moneymaker for Regeneron Pharmaceuticals is Eylea, an eye disease drug it makes in collaboration with Bayer (OTC:BAYRY). All net sales from Eylea in the U.S. are awarded to Regeneron, and the company splits with Bayer the revenue earned from markets outside of the U.S.
How are drug candidates tested?
Clinical testing: The drug candidate is tested on humans. Clinical testing generally occurs in three phases: 1 Phase 1: Small studies are conducted to find a safe dose for the drug candidate and determine how the drug affects humans. 2 Phase 2: Larger studies involving around 100 or more patients are conducted with a focus on safety and short-term side effects and to determine the optimal dose for the drug. 3 Phase 3: Even larger studies, with hundreds or even thousands of patients, are conducted to demonstrate how effectively and safely the experimental drug treats the target disease.
What is the name of the drug that is used to treat renal cell carcinoma?
Exelixis. Exelixis has developed four drugs that are already on the market. Its biggest winner by far is Cabometyx. The drug is approved for treating renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC), the most common types of kidney cancer and liver cancer, respectively.
Is Cabometyx approved for liver cancer?
The drug is approved for treating renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC), the most common types of kidney cancer and liver cancer, respectively. This biotech company could deliver solid growth in the future by expanding the use of Cabometyx as part of combination therapies. Exelixis and Bristol Myers Squibb (NYSE:BMY) ...
What is biotech company?
What exactly is a biotech? It’s a company that uses living organisms (for example, bacteria or enzymes) to make drugs. This use of living organisms differentiates biotechs from pharmaceutical companies, which use chemicals to develop drugs.
What is phase 1 of a drug?
Phase 1, which involves small studies designed to find a safe dose for the drug candidate and determine how it affects humans. Phase 2, which involves studies that can include around 100 or more patients and focus on safety, short-term side effects, and determining the optimal dose for the drug.
Can you buy marijuana stocks on Robinhood?
However, it means that several great U.S.-based pure-play marijuana stocks can't be bought on Robinhood since they can only trade over the counter due to cannabis being illegal at the federal level. Meanwhile, five Canadian marijuana stocks rank among the 100 most popular stocks on Robinhood. Here are three fast-growing pot stocks ...
Is Trulieve Cannabis profitable?
Trulieve Cannabis ( OTC:TCNNF) claims a key advantage over all of the stocks mentioned so far: It's already profitable. The U.S. cannabis operator has delivered positive and growing adjusted EBITDA in 10 consecutive quarters.
How many states does Curaleaf operate in?
While Canopy can only hope to enter the lucrative U.S. market, Curaleaf already operates in 23 states. It runs 95 dispensaries, 22 cultivation sites, and more than 30 processing facilities. Growth shouldn't be a problem at all for Curaleaf.
How many dispensaries does Curaleaf have?
It runs 95 dispensaries, 22 cultivation sites, and more than 30 processing facilities. Growth shouldn't be a problem at all for Curaleaf. Several of the states where it operates have cannabis markets only in their early stages.
Where is Green Thumb located?
The company recently opened its 49th retail cannabis store nationwide in Pennsylvania, which claims a fast-growing medical cannabis market.
